Dinutuximab Beta with chemotherapy for high-risk Ewing sarcoma
Treatments studied
Part of Cancer clinical trials.
This trial tests adding a drug called Dinutuximab Beta to standard chemotherapy for people with a newly diagnosed, high-risk type of Ewing sarcoma that has a certain marker (GD2) on the tumor cells. The goal is to see if this combination is safe and can help improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a newly diagnosed Ewing sarcoma (or a similar type) that is high-risk because it has spread to other parts of the body.
- Your tumor must have a protein called GD2 on its surface, confirmed by a central lab.
- You must be at least 12 months old.
- You need to have started your first round of standard chemotherapy and have had at least 14 days since your last dose.
- You must have adequate organ function, including bone marrow, liver, heart, and kidneys.
- You cannot be pregnant or breastfeeding, and must use effective birth control if applicable.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a personalized radiation therapy that adjusts the dose based on your tumor. It aims to improve treatment for Ewing sarcoma while limiting side effects.
This trial tests whether adding immunotherapy (a treatment that helps your immune system fight cancer) to chemotherapy can help young people whose bone or soft tissue sarcoma has come back or hasn't responded to previous treatment.
This trial tests a new immunotherapy that targets a specific protein change found in Ewing sarcoma and desmoplastic small round cell tumors (DSRCT). The therapy is designed to help your immune system recognize and attack cancer cells. It may be an option if you have already received standard chemotherapy and your tumor has a certain genetic marker.
This trial compares two different chemo combinations for Ewing's sarcoma that has not responded to first-line treatment. One group gets a special liposomal form of irinotecan plus temozolomide and vincristine; the other gets standard irinotecan with the same two drugs. The goal is to see which is safer and more effective.
This trial is testing a new drug called xaluritamig for children, teens, and adults with Ewing sarcoma that has come back or is not responding to treatment. The goal is to see if this drug can shrink the cancer or stop it from growing.
This Phase 2 trial studies naxitamab (a targeted antibody) in children and young adults whose Ewing sarcoma has come back or kept growing despite prior treatment. You may be eligible if the tumor shows a target called GD2 and if your heart, lungs, and past treatment recovery meet safety requirements.
Hear when a new High-risk GD2-Positive Ewing Sarcoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.